A First-in-Human, Open-Label Phase Ib and a Randomised, Double-Blind Phase IIa Clinical Trial in Recent-Onset Type 1 Diabetes with AG019 As Monotherapy and in Combination with Teplizumab

Adults and adolescents with type 1 diabetes diagnosed within 150 days were enrolled, with documented evidence of at least one autoantibody and a stimulated peak C-peptide level >0.2 nmol/l.